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Reovirus is an oncolytic virus (OV), which acts by both direct tumor cell killing and priming of antitumor immunity. A major obstacle
for effective oncolytic virotherapy is effective delivery of OV to tumor cells. Ovarian cancer is often confined to the peritoneal cavity
and therefore i.p. delivery of reovirus may provide the ideal locoregional delivery, avoiding systemic dissemination. However, ovar-
ian cancer is associated with an accumulation of ascitic fluid, which may interfere with oncolytic viral therapy. Here, we investigated
the effect of ascites on reovirus-induced oncolysis against primary ovarian cancer cells and ovarian cancer cell lines. In the absence
of ascites, reovirus was cytotoxic against ovarian cancer cells; however, cytotoxicity was abrogated in the presence of ascitic fluid.
Neutralizing antibodies (NAb) were identified as the cause of this inhibition. Loading OV onto cell carriers may facilitate virus deliv-
ery in the presence of NAb and immune cells which have their own antitumor effector activity are particularly appealing. Immature
dendritic cells (iDC), Lymphokine-activated killer (LAK) cells and LAKDC cocultures were tested as potential carriers for reovirus for
tumor cell killing and immune cell priming. Reovirus-loaded LAKDC, and to a lesser degree iDC, were able to: (i) protect from NAb
and hand-off reovirus for tumor cell killing; (ii) induce a proinflammatory cytokine milieu (IFNÇ, IL-12, IFNa and TNFa) and (iii) gener-
ate an innate and specific antitumor adaptive immune response. Hence, LAKDC pulsed with reovirus represent a novel, clinically
practical treatment for ovarian cancer to maximise both direct and innate=adaptive immune-mediated tumor cell killing.
Ovarian cancer is the leading cause of death amongst gynae-
cological malignancies and the fourth most common cause of
cancer-related deaths in women, with 125,000 deaths per
year, worldwide. The existing treatment for epithelial ovarian
cancer combines debulking surgery with platinum-based
chemotherapy; although initial treatment is generally success-
ful, relapse occurs in the majority of patients, with an overall
ﬁve-year survival rate for all stages of 40%.
Oncolytic viruses (OV) speciﬁcally replicate in and lyse
tumor cells. In addition to their direct cytotoxicity, OV stim-
ulate the immune system and facilitate the generation of
antitumor immune responses by releasing tumor-associated
antigens (TAA), danger signals and proinﬂammatory cyto-
kines into the tumor microenvironment.1–3 Reovirus is a nat-
urally occurring OV, which is cytotoxic against many tumor
types, including melanoma,4 breast,5 colorectal,6 prostate,2
ovarian7 and head and neck cancer,8 and has been investi-
gated in a number of clinical trials.9 A major limitation for
effective reovirus-based oncolytic virotherapy is the efﬁcient
delivery of OV to tumor cells in the presence of intact host
immunity. Since ovarian cancer often remains conﬁned to
the peritoneal cavity, intraperitoneal (i.p.) administration of
OV provides a potential locoregional delivery, direct to the
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tumor site, as an alternative to intravenous (i.v.) delivery.
However, ovarian cancer is often associated with accumula-
tion of ascitic ﬂuid in the peritoneal cavity. Ascites can
develop in numerous malignancies, including ovarian, endo-
metrial, colorectal, gastric, breast and pancreatic cancer. At
the time of diagnosis, 30% of ovarian cancer patients have
developed malignant ascites, which increases to 60% at the
time of death.10 As malignant ascites arises as a plasma exu-
date, it contains fractions of protein-rich plasma, including
antibodies. Hemminki et al. previously reported that neutral-
izing antibodies (NAb) against adenovirus are found in both
the plasma and ascites of ovarian cancer patients.11 Since
NAb bind viruses, block viral attachment to cell surface
receptors and inhibit viral infection, their presence may be
detrimental to oncolytic virotherapy. The presence of reovirus
speciﬁc NAb has been observed in the blood of patients
enrolled in reovirus clinical trials12–14; however, their pres-
ence in ascites has yet to be established.
Loading OV onto the surface of cell carriers or using
cells which internalize OV has been shown to be an effec-
tive mechanism to deliver virus to tumor in the presence of
NAb, predominantly in murine models, using carrier cells
as “Trojan horses,” which internalize the OV and are per-
missive for viral replication, but have no subsequent role
following OV delivery.15–17 However, there is variability in
terms of viral loading and “hitch-hiking” by carrier cells,
including between the mouse and human systems, both in
terms of whether the virus replicates in carrier cells during
transport and exactly how the virus is protected from NAb.
Currently, the precise mechanisms underlying how OV
behave on or in their carrier cells en route to their tumor
target remain largely undeﬁned. Viral internalization by car-
rier cells may allow better protection from NAb but will fail
if the carrier cell is killed before it reaches the tumor site.
In this regard, it is reassuring that reovirus is not toxic to
human DC, T cells18 or peripheral blood mononuclear cells
(PBMC).19 Additionally, using immune cells as carriers also
has the potential to provide additional antitumor activity,
either via direct cytotoxicity [e.g., natural killer (NK),
cytokine-induced killer (CIK) and lymphokine-activated
killer (LAK) cells], or by supporting the priming of adaptive
antitumor immune responses (e.g., DC and macrophages).
Combining oncolytic viral therapy with cellular immuno-
therapy may thus prove to be an effective dual cancer ther-
apy. For example, preclinical studies have demonstrated that
vesicular stomatitis virus (VSV) loaded onto tumor-speciﬁc
T cells and vaccinia virus (VV) loaded onto CIK cells can
enhance antitumor therapy compared with either agent
alone.20,21
LAK cells (a heterogeneous population of activated T,
NK and NKT cells), which can be easily cultured in large
numbers from patients, have shown some promise as a cel-
lular agent for cancer therapy and have been used clinically
with IL-2 for the treatment of ovarian cancer.22,23 LAK
cells show speciﬁc antitumor activity against autologous
ovarian tumor cells and can be expanded ex vivo in the
presence of IL-2. However, whilst LAK cells alone were
well tolerated (up to 1011 cells per infusion), concomitant
systemic delivery of IL-2 to patients resulted in signiﬁcant
toxicities, including vascular leakage and hypotension.
Coculture of LAK cells with DC (LAKDC) has been
reported to eliminate the need for coadministration of IL-2,
due to bi-directional signaling supporting LAK cell activa-
tion and viability, as well as inducing DC maturation and
the production of proinﬂammatory cytokines.24–26 In vivo
studies have shown that the combination of LAKDC can
effectively eradicate subcutaneous tumors, leading to the
generation of antitumor immunity, whereas treatment with
either cell type alone was ineffective.27 Previous studies
have also highlighted DC as effective cell carriers for reovi-
rus in the presence of neutralizing serum for the treatment
of melanoma. DC protected reovirus from antibody neu-
tralization by internalization of viral particles, making reo-
virus unavailable for NAb binding.18 The use of DC in
combination with LAK cells may, therefore, provide effec-
tive cell carriage for reovirus, leading to antitumor
responses mediated by direct cytotoxicity and=or the gener-
ation of antitumor immunity.
Here, we show that ovarian cancer cell lines and pri-
mary ovarian cancer cells established from patients are sus-
ceptible to reovirus-induced oncolysis; however, this direct
cytotoxicity was abrogated if malignant ascites was present.
The inhibitory factor present in the ascites was identiﬁed
as NAb, which could be found in equal concentrations in
both the plasma and ascites of ovarian cancer patients.
Loading reovirus onto either immature dendritic cells
(iDC) or LAKDC overcame antibody neutralization and
reovirus-loaded LAKDC were optimal for delivering reovi-
rus for direct tumor cell killing and innate and adaptive
immune priming.
What’s new?
Oncolytic viruses (OVs) specifically infect and kill tumor cells. In this study, the authors began to examine whether
intraperitoneal delivery of an OV could be effective against ovarian cancer. They found that, while the virus does kill ovarian-
cancer cells in vitro, this effect is blocked when ascites fluid is added. Cytotoxicity can be restored, however, by using a
combination of lymphokine-activated killer and dendritic cells (LAKDC) as carriers, which protect the virus from neutralizing
antibodies in the ascites. The LAKDC combination may also support subsequent adaptive immune priming.
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Material and Methods
Reovirus
Reovirus Type 3 Dearing strain was provided by Oncolytics
Biotech and stored at neat concentrations in PBS at 4C
(up to a month) or at 280C (long-term storage). Virus
titre was determined by standard plaque assays using L929
cells.
Cell culture
Human cell lines, Skov-3, OVCA433, TR175 and Daudi,
were grown in Roswell Park Memorial Institute-1640
medium (RPMI-1640; Sigma) supplemented with 10 % (v=v)
fetal calf serum (FCS; Biosera) and 2 mmol=L glutamine
(Sigma). L929 and Mel-888 cells were grown in Dulbecco’s
Modiﬁed Eagle’s Medium (Sigma) supplemented with 10%
(v=v) FCS and 2 mmol=L glutamine. PBMC were derived
from buffy coats of healthy donors by Ficoll-Hypaque density
gradient centrifugation. iDC were generated from monocytes
isolated from PBMC using anti-CD14 magnetic beads (Milte-
nyi Biotec) and cultured in RPMI-1640 supplemented with
10% (v=v) FCS, 2 mmol=L glutamine, 800 U=mL GM-CSF
(R&D Systems) and 500 U=mL rhIL-4 (R&D Systems) for 7
days. LAK cells were generated from the CD14 negative frac-
tion of PBMC by culturing in RPMI-1640 supplemented with
10% (v=v) FCS, 2 mmol=L glutamine and 500 U=mL rhIL-2
(ProleukinVR ) for 7 days.
Ovarian cancer samples
Ovarian cancer patients (all serous adenocarcinomas, Stages
III–IV) undergoing routine paracentesis were identiﬁed and
informed consent was given to collect ascitic ﬂuid in
accordance with local institutional ethics review and
approval. Ascitic ﬂuid was centrifuged at 450g for 10 min;
ﬂuid was collected and stored at 4C or 220C for long
term storage. Primary ascites-derived cancer cells were cul-
tured in RPMI-1640 containing 10% (v=v) FCS, 7.5% (v=v)
autologous ascitic ﬂuid and 2 mmol=L glutamine. Tumor
cells were identiﬁed by positive staining of CA125 (Gene-
Tex) using ﬂow cytometry and used at low passage numbers
(p1-p4).
Reovirus infection of ovarian cancer cells
Ovarian cancer cell lines and ascites-derived cancer cells
were seeded at 1 3 105 in the presence or absence of 2.5%
(v=v) ascitic ﬂuid. Matched autologous cells and ascites
were available for four patient samples. Reovirus was added
to adherent cells at indicated concentrations. Cells were
then cultured for denoted times before viability was
determined.
Live=deadVR viability assay
Cell viability was determined using the Live=deadVR viability
assay (Life Technologies) following manufacturer’s instruc-
tions. Cells were acquired on a FACS Calibur (Becton-Dick-
inson) and percentage of cell death determined.
Ascites and plasma neutralization
L929 cells were seeded into a ﬂat bottomed 96-well plate at a
cell density of 2.5 3 104 cells=well. Halving dilutions of
plasma and ascites samples were prepared before the medium
was removed from L929 cells and replaced with the plasma-
and ascites-diluted medium. Cells were infected with reovirus
at 0.05 pfu=cell or left uninfected for 100% viable control.
After 48 hr, MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) (5 mg=mL; Sigma) was added
to wells and incubated for 4 hr at 37C. Medium was removed
and cells solubilized using 100% DMSO (Fisher Scientiﬁc).
Optical density was determined using a Multiskan EX plate
reader (Thermo Electron) at a wavelength of 550 nm.
Removal of human IgG from ascites
Protein A Resin-Higher Binding Capacity (GenScript) was
used to isolate IgG from the ascites, following manufacturer’s
instructions.
Immunoprecipitation of reovirus from ascites
Reovirus (5 3 105 pfu) was incubated in ascites for 30 min,
before the addition of protein A resin. Resin and ascites were
incubated for 2 hr at 4C; IgG was then removed as above.
The IgG samples were then analyzed by standard western
blotting for reovirus r3 protein (clone 4F2; DSHB).
Reovirus loading of carrier cells
Carrier cells (iDC and LAK cells) were resuspended at 5 3
106 cell=mL in PBS; LAKDC cocultures were set up at a 1:1
ratio, using 5 3 106 cells=mL of each cell type. Cells were
incubated 6 reovirus for 3–4 hr at 4C; the amount of reovi-
rus added was the same in all 3 cultures: 1 pfu=cell for single
cell cultures and 0.5 pfu=cell in LAKDC cocultures. Reovirus-
loaded cells were washed twice with PBS to remove any
unbound reovirus.
Reovirus retention and replication
Reovirus-infected and -loaded cells were collected at indi-
cated time points and subjected to three cycles of freeze-thaw
lysis. Reovirus retention and replication was determined by
standard plaque assay on L929 cells.
Reovirus hand-off in the presence of ascites
Reovirus-loaded iDC, LAK and LAKDC were added to
adherent TR175 cells at a 1:1 ratio 6 2.5% ascitic ﬂuid. After
4 hr, medium containing carrier cells was removed and
replaced with medium 6 2.5% ascites. TR175 cells were cul-
tured for a further 72 hr and viability determined by Live-
deadVR assay.
Chromium release assay
Cytotoxicity was measured using chromium release assays.
Skov-3, OVCA433 and Daudi targets were incubated with
100 mCi 51Cr (Perkin Elmer) for 1 hr, washed three times
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with a large volume of Hanks Balanced Salt Solution (HBSS;
Sigma) and incubated with effectors at indicated ratios.
51Chromium release was determined using a 1450 Microbe-
tJet Scintillation Counter (Perkin Elmer) and the results were
expressed as percent speciﬁc target lysis, using the formula:
% Lysis51003ðsample cpm2spontaneous release cpmÞ=
ðmaximum release cpm2spontaneous release cpmÞ
Flow cytometry
A FACS Calibur was used for acquisition and analysis was
performed using Cell Quest Software, v4.0.1 (BD Bioscien-
ces). Antibodies: antihuman CD80-PE, CD86-PE, CD11c-
FITC, CD107a-FITC, CD107b-FITC and CD8-PerCP (all BD
Pharmingen).
ELISA
Human IFNÇ, TNFA, IL-12p70 (BD Pharmingen), IFNA and
IgG (both Mabtech) ELISA assays were carried out using
matched antibody pairs, according to the manufacturer’s
instructions.
Generation of tumor specific cytotoxic T cells (CTL)
Reovirus (1 pfu=cell) or iDC, LAK and LAKDC loaded with
reovirus (1 pfu=cell) were cultured with Skov-3 cells (1:1
ratio) for 24 hr. Nonadherent cells were harvested and co-
cultured with autologous PMBC at a ratio of 1:10 to 1:40 in
CTL medium [RPMI-1640 supplemented with 7.5% (v=v)
human AB serum (Biosera), 2 mmol=L glutamine, 1% (v=v)
sodium pyruvate, 1% (v=v) non-essential amino acids, 1%
(v=v) Hepes, 20 lmol=L b-mercaptoethanol (all Sigma)] and
5 ng=mL rhIL-7 (R&D Systems). Cultures were re-stimulated
weekly using the same protocol.
CD107 degranulation assay
CTL and tumor targets were incubated at a 1:1 ratio; after
an hour anti-CD107a- and CD107b-FITC, anti-CD8-PerCP
and Brefeldin A (10 lg=mL; Sigma) was added. After a fur-
ther 4 hr, CTL were washed and analyzed by ﬂow
cytometry.
Statistics
One-way ANOVA was used to determine statistical
signiﬁcance.
Results
Ascites inhibits reovirus-induced oncolysis and replication
Whilst reovirus-induced oncolysis of ovarian cancer cell lines
has been previously demonstrated,7 the effects of reovirus-
induced oncolysis on primary human ovarian cancer cells
and its effects in the context of ascitic ﬂuid have not been
examined. In the absence of ascites, reovirus was cytotoxic
against three established ovarian cancer cell lines, Skov-3,
OVCA433 and TR175 (Fig. 1a) and, importantly, against 10
primary ovarian cancer cell samples freshly isolated from
patients’ ascites, albeit with varying sensitivities (Fig. 1c).
However, in the presence of 2.5 % ascitic ﬂuid, reovirus-
induced cytotoxicity was signiﬁcantly inhibited in all cell lines
and in four out of four patient tumor samples cultured in
autologous ascites (Figs. 1a and 1d). Reovirus replication was
also examined following infection of ovarian cancer cells 6
ascites. In the absence of ascites, reovirus readily replicated in
ovarian cancer cell lines (Fig. 1b) and primary ovarian cancer
cells (Fig. 1e, although at 10- to 1000-fold lower levels than
those detected in cell lines). However, in the presence of asci-
tes, reovirus replication, in line with tumor cell killing, was
signiﬁcantly abrogated (Figs. 1b and 1e).
Antibodies present in ascites are responsible for blocking
reovirus-induced oncolysis
To determine whether the inhibition of reovirus was ascites-
speciﬁc or systemic, matched plasma and ascites samples from
ovarian cancer patients were analyzed. Both plasma and ascites
inhibited reovirus-induced cytotoxicity to a similar level, as
seen by neutralization of L929 cell death (Fig. 2a). These data
suggest a systemic inhibitory factor was responsible; hence, we
hypothesized that NAb may play a role in reovirus inhibition.
To establish whether reovirus was directly bound to NAb in
the ascites, immunoprecipitation assays were performed. Reo-
virus r3 capsid protein was successfully immunoprecipitated
with IgG in six ascites samples tested; a representative blot is
shown in Figure 2b. Furthermore, removing IgG from the asci-
tes, conﬁrmed by ELISA (Fig. 2c), signiﬁcantly restored
reovirus-induced cytotoxicity (Fig. 2d), indicating a major role
for IgG inhibiting reovirus-induced cell death in ascites. To
determine whether complement proteins were also involved in
the inhibition of reovirus, ascites samples were heated to 56C
for 30 min to inactivate complement before neutralization
assays were performed. There was no difference observed in
reovirus-induced cytotoxicity when comparing heat-
inactivated ascites to nonheat-inactivated ascites (Fig. 2e), or
heat inactivated plasma versus nonheat inactivated plasma
(data not shown), conﬁrming that complement was not
involved in the inhibition of reovirus.
iDC and LAKDC deliver reovirus to tumor cells in the
presence of neutralizing ascites
Whilst reovirus has previously been successfully loaded onto
human iDC for tumor delivery,18 the ability of LAK cells or
LAKDC cocultures to carry and protect reovirus from NAb,
has not been investigated. To ﬁrst identify their suitability as
potential viral carriers, iDC, LAK cells and LAKDC cocul-
tures were loaded with reovirus and their levels of reovirus
retention and replication determined by plaque assay.
Approximately 5% of input virus was retained by all cell pop-
ulations (Fig. 3a) and no reovirus replication was detected up
to 72 hr postloading (data not shown). In addition, for iDC
and LAK cells to be effective cell carriers and provide addi-
tional antitumor effects, it was important to establish that
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they remained viable following reovirus-loading. Viability
studies showed no signiﬁcant increase in death 48 hr post-
reovirus loading (Fig. 3b). Next, the ability of iDC, LAK cells
and LAKDC cocultures to deliver reovirus to tumor cells in
the presence of NAb was investigated. Neat reovirus and
reovirus-loaded iDC, LAK and LAKDC (iDC-reo, LAK-reo
and LAKDC-reo) were cultured with TR175 cells at a 1:1
ratio for 4 hr 6 2.5% ascitic ﬂuid. Carrier cells were removed
to exclude cell-mediated TR175 cytotoxicity (no TR175 cell
death was detected at 4 hr at this E:T ratio – data not
shown), and tumor cells were cultured (6 2.5% ascitic ﬂuid)
for a further 72 hr to investigate reovirus-induced cytotoxic-
ity. Figure 3c shows that levels of tumor cell death in the
presence of ascites following iDC-reo and LAKDC-reo viral
hand-off were signiﬁcantly greater than for neat reovirus or
LAK-reo delivery. These data indicate that iDC or LAKDC
cocultures are effective cell carriers for delivering reovirus to
tumor cells in the presence of NAb.
Reovirus-loaded LAKDC induce ovarian cancer cell death
Having determined that iDC and LAKDC have the potential
to deliver oncolytic reovirus to tumors in the presence of NAb
to induce virus-mediated cytotoxicity, we next investigated
whether these carrier cells could provide additional immune-
mediated antitumor effects. As reovirus-loaded LAK cells were
unable to shield the virus from neutralization, they were not
investigated further (Fig. 3c). To determine the cytotoxic
potential of iDC and LAKDC cell carriers alone 6 loading
Figure 1. Malignant ascites inhibits reovirus-induced oncolysis. Ovarian cancer cell lines, Skov-3, OVCA433 and TR175 were infected with
reovirus (1 pfu=cell) 6 2.5% ascitic fluid (2 separate samples; AF1 and 2). (a) Cell viability was determined using the Live=deadVR viability
assay and flow cytometry 48 hr postinfection (p.i.). Graphs show the mean percentage cell death 1 SEM from three independent experi-
ments. (b) Reovirus replication was determined by plaque assay using L929 cells and fold increase was calculated from initial input reovi-
rus. Graphs show mean fold increase of reovirus titres 1 SEM at 72 hr p.i. from three independent experiments. (c) Primary ascites-derived
ovarian cancer cells from 10 patients were infected 6 reovirus (10 pfu=cell) and cell viability was determined 48 hr p.i. using the Live-
deadVR assay. (d) Four primary samples were infected with reovirus (10 pfu=cell) 6 2.5% autologous ascitic fluid (samples AF3, 4, 5 and 6)
for 24, 48 and 72 hr and cell viability determined as above. Graph shows the mean percentage cell death 1 SEM from four patient sam-
ples. (e) Reovirus replication was determined in primary ascites-derived ovarian cancer cells. Cells were infected with reovirus (1 pfu=cell)
for 24, 48 and 72 hr 6 2.5% autologous ascitic fluid (samples AF3, 4 and 7) and reovirus replication determined as in (b). Graph shows
the mean 1 SEM from three patient samples (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001).
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with reovirus, in the presence of ascites, chromium release
assays were performed. LAKDC, unlike iDC, were cytotoxic
against Skov-3 and OVCA433 cells and loading reovirus onto
either LAKDC or iDC further increased tumor cell death (Fig.
4a and 4b). We reasoned this additional cytotoxicity following
the loading of reovirus could be either direct viral cytotoxicity,
or related to an alternative indirect immune mechanism
whereby reovirus augments the cytotoxic effects of NK cells.28
To explore these alternatives, the ability of reovirus to enhance
LAKDC-induced cytotoxicity was investigated using Daudi as
a target cell line, which is known to be resistant to direct reo-
virus oncolysis. LAKDC-reo were able to kill Daudi targets,
but there was no difference between LAKDC and LAKDC-reo
cytotoxicity (Fig. 4c), implying that reovirus did not enhance
immune LAKDC-mediated cytotoxicity; rather, any increased
killing by LAKDC-reo over LAKDC in Figure 4a was probably
Figure 2. Reovirus inhibition is IgG-mediated. (a) L929 cells were infected with reovirus (0.05 pfu=cell) for 48 hr in the presence of serial
dilutions of matched patient plasma and ascites (AF7). L929 cell viability was determined by MTT assay and normalized to uninfected con-
trol. Graph is representative of five patient samples. (b) IgG was immunoprecipitated from ascites, which had been incubated 6 reovirus
(5 3 106 pfu) using protein A resin, then probed for reovirus r3 protein (41 kDa MW) by western blotting. MW: molecular weight marker;
Lane1: ascites (AF3) 1 protein A resin (no reovirus); Lane 2: protein A resin 1 reovirus [no ascites (IgG)]; Lane 3: ascites (AF3) 1 reovirus 1
protein A resin. Blot is representative of six ascitic samples. IgG-depleted ascites samples were collected by centrifugation following
protein A resin incubation. (c) IgG concentration in ascites before and after IgG depletion was determined by ELISA. (d) L929 cells
were infected 6 reovirus (0.05 pfu) either in the presence of ascites, IgG-depleted ascites or in the absence of ascites, for 48 hr. Cell
viability was determined by MTT assay and normalized to uninfected control. Graphs shows representative ascitic sample, AF9, of three
samples (AF1, 2 and 9). (e) L929 cells were infected with reovirus (0.05 pfu=cell) for 48 hr in the presence of serial dilutions of
matched ascites 6 heat inactivation (AF10). L929 cell viability was determined by MTT assay and normalized to uninfected control.
Graph is representative of three patient samples (**p < 0.01).
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due to viral, rather than immune effects. Similarly, additional
DC-reo cytotoxicity against Daudi targets was not seen (Fig.
4c). Overall, these data support the potential use of LAKDC as
carriers of reovirus in vivo for ovarian cancer, to instigate
innate immune-mediated cytotoxicity in the presence of NAb,
together with reovirus-induced oncolysis.
LAK cells and reovirus can mature iDC in the presence
of ascites
Previous studies have demonstrated the ability of both LAK
cells and reovirus to mature iDC, an essential step for gener-
ation of antigen-speciﬁc adaptive T cell antitumor immu-
nity.25,28 However, whether this applies in the context of
Figure 4. Reovirus-loaded LAKDC are more cytotoxic towards ovar-
ian cancer cells than reovirus-loaded iDC. Cytotoxicity of reovirus-
loaded iDC and LAKDC was determined by chromium release
assay. (a) Skov-3 and (b) OVCA433 targets were labeled with chro-
mium and cultured with iDC-reo or LAKDC-reo in the presence of
2.5% ascites (AF11, 12 and 13) at indicated E:T ratios for 48 hr.
Graphs show the mean percentage cell death 1 SEM from three
healthy donors. (c) Daudi cells were labeled with chromium and
incubated with neat reovirus (1 pfu=cell), reovirus-loaded or -
unloaded iDC and LAKDC at indicated E:T ratios for 48 hr. Graph
shows the mean percentage cell death 6 SEM from three healthy
donors (*p < 0.05, ***p < 0.001).
Figure 3. Reovirus-loaded iDC and LAKDC can deliver reovirus for
tumor cell killing in the presence of ascites. Reovirus was loaded
onto iDC, LAK cells and LAKDC cocultures (1pfu=cell) and either
quantified for: (a) Percentage of reovirus retention by plaque assay
or (b) Cytotoxicity by Live=deadVR viability assay at 48 hr post-
loading. Graphs show the mean 1 SEM of three healthy donors.
(c) TR175 were treated with neat reovirus or reovirus-loaded onto
iDC, LAK cells and LAKDC (iDC-reo, LAK-reo and LAKDC-reo) for 4 hr
6 2.5% ascites. Carrier cells were then removed and replaced with
growth media 6 ascites; TR175 cell viability was then determined
72 hr p.i. by Live=deadVR viability assay. Graph shows mean per-
centage of cell death 1 SEM from five healthy donors using two
ascitic fluids (AF1 and 7; *p < 0.05).
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malignant ascites, which may contain immunosuppressive
factors that might impede DC maturation, has not been
addressed. The ability of LAK cells and reovirus to pheno-
typically mature iDC in the presence of ascites was investi-
gated by ﬂow cytometry. Unloaded LAK cells induced cell
surface expression of the activation=maturation markers,
CD86 and CD80, on iDC to the same extent in both the
absence and presence of ascitic ﬂuid (Supporting Information
Fig. S1). CD86 was further increased in reovirus-loaded
LAKDC cocultures and, again, this was not impeded by the
presence of ascitic ﬂuid (Fig. 5a), suggesting that both LAK
and reovirus can overcome potentially suppressive factors in
the ascites.
Reovirus-loaded LAKDC induce a proinflammatory cytokine
milieu
A key determinant of adaptive immune priming following
DC maturation is the proﬁle of appropriate cytokines
(including TNFa, IFNa, IL-12p70 and IFNÇ) secreted within
the tumor microenvironment. In the absence of ascites, load-
ing reovirus onto both iDC and LAKDC signiﬁcantly induced
the secretion of TNFa and IFNa, whilst the production of
IL-12p70 and IFNÇ was increased by reovirus in LAKDC-reo
cultures compared with LAKDC alone [only low levels of
cytokines were detected on reovirus loading of iDC alone
(Supporting Information Fig. S2)]. Hence, LAKDC-reo may
have the potential to reverse the immunosuppressive tumor
microenvironment and promote priming of adaptive antitu-
mor immunity following tumor cell death. To determine
whether the production of IFNa, a key cytokine in reovirus-
mediated immune cell cross-talk,19 which is also central to
adaptive immune priming,29 was affected in the presence of
ascites, levels were measured in iDC-reo and LAKDC-reo
cultures 6 ascites (iDC and LAKDC do not produce IFNa
in the absence of reovirus–data not shown). Figure 5b shows
that the presence of ascitic ﬂuid did not signiﬁcantly inhibit
the production of IFNA from either LAKDC-reo or DC-reo.
Reovirus-loaded LAKDC prime antitumor immunity in the
presence of malignant ascites
Finally, to test the ability of reovirus or reovirus-loaded cells
to generate a tumor speciﬁc adaptive immune response in
the presence of ascites, an in vitro priming assay was per-
formed. Skov-3 cells were cultured with reovirus, iDC-reo or
LAKDC-reo for 24 hr, after which the nonadherent cells
were harvested [containing antigen-loaded antigen presenting
cells (APC)] and cultured with autologous PBMC. CTL were
restimulated up to twice more. One week after the ﬁnal
restimulation, tumor-speciﬁc cytotoxic activity was measured
using CD107 degranulation assays against Skov-3 and irrele-
vant Mel-888 targets. Both neat reovirus and iDC-reo gener-
ated some CTL responses, reﬂected by low level speciﬁc CD8
degranulation against Skov-3 cells (Fig. 6a); however, the
highest levels of adaptive response were seen after priming
initiated by LAKDC-reo. This is consistent with the ability of
LAKDC-reo to kill tumor cells for antigen release in an
inﬂammatory milieu, via both direct oncolysis and innate
immune mechanisms, even in the presence of ascitic NAb.
Over multiple experiments, LAKDC-reo generated signiﬁ-
cantly higher proportions of anti-Skov-3 CTL responses than
neat reovirus, although the superiority of LAKDC-reo over
iDC-reo did not reach statistical signiﬁcance (Fig. 6b). The
ability of LAKDC-reo to generate the highest proportion of
anti-Skov-3 CTL may be due to greater killing for antigen
release (Fig. 4) and=or the enhanced production of pro-
inﬂammatory cytokines (Supporting Information Fig. 2).
Taken together, these data suggest that LAKDC are consum-
mate cell carriers for reovirus, allowing delivery of reovirus
Figure 5. LAKDC and reovirus phenotypically mature iDC and produce proinflammatory cytokines in the presence of ascites. (a) Reovirus-
loaded iDC or LAKDC were cultured in the absence (red line) or presence of 2.5% AF5 (green line) or AF14 (blue line) for 48 hr. DC
(CD11c1 cells) were analyzed by flow cytometry for expression of maturation=activation markers, CD80 and CD86. Histogram plots are rep-
resentative of two healthy donors. Shaded gray 5 isotype control, black line 5 unloaded DC controls [either iDC (left panel) or DC within
LAKDC coculture (right panel)]. (b) Reovirus-loaded iDC and LAKDC were cultured for 48 hr 6 ascites (AF5 and 14) before supernatants
were collected and concentrations of IFNa were determined by ELISA. Graphs show the mean 1 SEM of four healthy donors.
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for tumor cell oncolysis, additional innate immune-mediated
killing, production of proinﬂammatory cytokines and ma-
turation of iDC to support adaptive antitumor immune
priming.
Discussion
Ovarian cancer remains a disease with a poor prognosis,
despite initial sensitivity to chemotherapy. Reovirus is one of
a range of OV which is being tested.9 Although we have
shown in patients that i.v. “neat” reovirus is able to selectively
access tumors in patients by evading NAb via hitchhiking on
cells in the blood,30 the delivery and efﬁcacy of OV may be
improved if they are ﬁrst pulsed ex vivo into carrier cells to
enhance OV protection and=or provide additional immune-
mediated antitumor cytotoxicity. In the case of ovarian cancer,
OV can be delivered by i.v. or i.p. routes (both are currently
being tested clinically in reovirus trials); however, regardless
of the administration technique, once the virus reaches the
tumor microenvironment (often restricted to the peritoneum
in ovarian cancer), it will inevitably encounter potentially
inhibitory factors. In the case of advanced ovarian cancer, the
associated ascitic ﬂuid is known to contain immunosuppres-
sive cytokines, such as IL-10,31 TGF-b32,33 and VEGF,33 which
could impair the immune-mediated component of OV ther-
apy and=or the effector function of virus-loaded immune cell
carriers. Moreover, the direct oncolytic effect of OV against
ovarian cancer could be compromised by NAb or other antivi-
ral components within ascites.
In this study, we have shown that ovarian cancer cell lines
and primary ovarian cancer cells are sensitive to reovirus-
induced oncolysis; however, this susceptibility is abrogated
when malignant ascitic ﬂuid is present (Fig. 1). We hypothe-
sized that NAb, which are present at baseline in the blood and
rise upon administration of reovirus in cancer patients, were
present in the ascites of ovarian cancer patients and responsi-
ble for inhibition of oncolysis. We found that matched plasma
and ascites samples similarly inhibited reovirus-induced cyto-
toxicity (Fig. 2a), suggesting that a common factor was indeed
responsible for reovirus inhibition. The presence of antireovi-
ral antibodies in ascites was conﬁrmed by immunoprecipta-
tion of reovirus with IgG (Fig. 2b), and depletion of IgG fully
restored reovirus-induced oncolysis, conﬁrming IgG was
responsible for viral inhibition (Figs. 2c and 2d). Heat inacti-
vation of ascites=plasma did not affect the ability of ascites=-
plasma to reduce oncolysis (Fig. 2e and data not shown),
indicating that complement proteins do not play a role in reo-
virus inhibition. These ﬁndings are consistent with previous
data demonstrating that removal of IgG from ascites improves
adenoviral infection.11,34 Hence, strategies that prevent neu-
tralization of reovirus are important for enhancing viral deliv-
ery to tumor cells and direct cell killing.
Previous studies, from our own and other laboratories,
have shown that OV can be delivered to tumors in the pres-
ence of neutralizing serum via immune cell carriers,15,21 and
that internalization of the virus may be the mechanism by
which OV are protected from NAb.18 As immune cells can
have direct antitumor effects, using them as carriers of OV
could provide additional therapy. We have shown that DC
are effective cell carriers of reovirus for the treatment of mel-
anoma,18 and there is evidence that the addition of LAK cells
to DC may generate a clinically practical and effective cellular
immunotherapy.27 We, therefore, hypothesized that LAKDC
co-cultures could be used as carriers to deliver reovirus to
ovarian cancer to: (i) protect from NAb in the circulation
and=or the tumor microenvironment for delivery to target
malignant cells; (ii) provide additional early innate tumor cell
Figure 6. Reovirus-loaded LAKDC prime antitumor immunity in the presence of ascites. Skov-3 cells were infected with either reovirus, iDC-
reo or LAKDC-reo in the presence of 2.5% ascites (AF4) for 24 hr. Nonadherent carrier cells=dead tumor cells were removed and cultured
with autologous PBMC for a week. CTL were restimulated weekly and tumor specific CTL activity measured in a CD107 assay against spe-
cific Skov-3 targets or irrelevant Mel-888 targets. (a) FACS plots are representative of three donors and the percentage of CD8 cells degra-
nulating against targets is shown. (b) Graph shows the mean percentage 1 SEM of CD8 cells degranulating against Skov-3 targets from
three healthy donors (*p < 0.05).
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killing via LAK cells and (iii) support priming of adaptive
antitumor immunity via DC.
In this study, we have focused on preclinical human in vitro
model systems, including the use of fresh patient samples com-
prising tumor cells and ascites. We have not used murine mod-
els because there are signiﬁcant differences between the effects
of reovirus in mouse and human systems; for example, human
DC protect reovirus from NAb by internalizing the virus with-
out cell toxicity or viral replication, whilst murine DC support
reovirus replication and die after infection.15,18 Moreover,
human data are more directly relevant to clinical application,
and we have previously shown LAKDC represent a practical
immunogenic mixed cell population, which can readily be pre-
pared to clinical grade from patient blood.25
Reovirus could be successfully loaded on=in to iDC, LAK
cells and LAKDC cocultures without affecting the cells’ via-
bility, and iDC and LAKDC could protect and hand-off reo-
virus to tumor cells in the presence of neutralizing ascites,
whilst LAK cells and neat reovirus could not (Fig. 3). The
mechanism(s) by which DC release reovirus following protec-
tive internalization18 remain unclear. Another RNA virus
(HIV-1) can be transmitted from DC to T cells via exocytosis
of exosomes,35 whilst reovirus can be released from endothe-
lial cells without associated apoptosis or lysis.36 Reovirus viri-
ons have also been reported to localize to recycling
endosomes, suggesting a further mechanism by which the
virus may be released.37 However, how reovirus is delivered
from carrier to target tumor cells to initiate oncolysis remains
an important area of future study. Both LAKDC and
LAKDC-reo were more cytotoxic against ovarian targets than
iDC and iDC-reo, respectively, conﬁrming additional innate
immune killing in the presence of LAK cells only (Fig. 4).
The increased cytotoxicity following reovirus loading of either
LAKDC or iDC populations was probably due to viral-,
rather than immune-, mediated cell death, since enhanced
cytotoxicity was lost when reovirus-resistant Daudi cells were
used as targets. LAK cells and reovirus phenotypically
matured iDC in the presence of ascites (Supporting Informa-
tion Fig. S1 and S5a), and hence, may be able to mature sup-
pressed resident iDC (unpublished data). Loading reovirus
into LAKDC cocultures also increased production of the
immunostimulatory cytokines, IFNÇ, TNFa, IFNa and IL-
12p70, potentially reversing the suppressive nature of the
tumor milieu to support generation of effective T cell
responses (Supporting Information Fig. S2).
As the presence of intra-tumoral T cells in ovarian and
other cancer patients has been shown to result in improved
survival,38 we also tested whether reovirus-loaded carrier cells
could support generation of CTL against ovarian cancer, using
our previously established model of human in vitro priming of
antitumor adaptive immunity.39 In the presence of ascites,
LAKDC-reo were most effective at generating anti-Skov-3
CTL, and were signiﬁcantly better than neat reovirus (Fig. 6).
In summary, LAKDC-reo may represent a clinically prac-
tical therapy, which has the potential to be both an effective
direct cytotoxic and innate=adaptive immunotherapy for
ovarian cancer, even in the presence of ascites, which con-
tains antiviral NAb. Clinical studies are warranted and in
development to test this approach further in patients by
administering LAKDC-reo via i.v. and i.p. routes.
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